DEVELOPMENT OF DRUGS ACTING AT ADENOSINE RECEPTORS

作用于腺苷受体的药物的开发

基本信息

项目摘要

The extracellular adenosine receptor has a modulatory role in the nervous, circulatory, endocrine, and immunological systems. The prospect of harnessing these effects specifically for therapeutic purposes is attractive. We have developed research tools for the characterization of adenosine receptors in vitro and in vivo. We have synthesized new drug analogues and elucidated structure activity relationships at receptor subtypes. Derivatives of adenosine with chemical modifications at the N6 and C-2 positions of the purine ring act as selective adenosine agonists. Al- agonists are being explored as cerebroprotective agents. To enhance brain uptake, prodrug schemes are being examined. APEC, and A2 selective adenosine amine congener served as the basis for a photoaffinity labeling reagent that allowed the first determination of the molecular weight of the receptor. Functionalized congeners of xanthines act as potent adenosine antagonists and are being developed as radioactive tracers for adenosine receptors and as affinity labels. Peripherally selective adenosine agonists have been developed. Since the two major subtypes of adenosine receptors have been cloned it has been possible to conduct molecular modeling of the receptor protein, based on sequence analyses and computerized energy minimizations. A hypothesis concerning the mode of binding to ligands to adenosine receptors has been derived. This hypothesis is consistent with pharmacological observations and site directed mutagenesis experiments, in which key histidyl residues have been replaced by other amino acids.
胞外腺苷受体在细胞凋亡中起调节作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

K JACOBSON其他文献

K JACOBSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('K JACOBSON', 18)}}的其他基金

FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    3776296
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    3839856
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    3875623
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF DRUGS ACTING AT ADENOSINE RECEPTORS
作用于腺苷受体的药物的开发
  • 批准号:
    3754192
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF DRUGS ACTING AT ADENOSINE RECEPTORS
作用于腺苷受体的药物的开发
  • 批准号:
    3839858
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    3964198
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    3754190
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
PROSTHETIC GROUPS FOR RADIOLABELING OF FUNCTIONALIZED DRUGS AND PEPTIDES
用于功能化药物和肽的放射性标记的辅基
  • 批准号:
    3875624
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF DRUGS ACTING AT ADENOSINE RECEPTORS
作用于腺苷受体的药物的开发
  • 批准号:
    5201968
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
FUNCTIONALIZED CONGENERS OF BIOACTIVE COMPOUNDS
生物活性化合物的功能化同系物
  • 批准号:
    4689207
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了